GSK plc 6-K, filed May 6, 2020
GSK plc (GSK)
6-K
2020-05-06
For: 2020-05-06
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on May 6, 2020.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of May 2020
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
GlaxoSmithKline plc
Results of Annual General Meeting
GlaxoSmithKline
plc ('GSK') held its Annual General Meeting ('AGM') at 2.30pm on
Wednesday 6 May 2020.
As
a result of the COVID-19 pandemic and the prohibition on public
gatherings of more than two people, the AGM was held as a closed
meeting attended by the minimum necessary quorum of two
shareholders. All valid proxy votes (whether submitted
electronically or in hard copy form) were included in the poll
taken at the meeting.
All resolutions were passed at the AGM and the
results of the poll are set out below. The full text of the
resolutions considered at the AGM are contained in the Notice of
AGM published on 23 March 2020 which is available on GSK's website
at www.gsk.com.
Commenting
after the shareholder webcast, which was held after the AGM, Sir
Jonathan Symonds, Chairman, said "Despite the current crisis which
unfortunately meant that we could not hold our AGM in the usual
way, I was pleased that we could engage with our shareholders via
the webcast and that we were able to answer a number of questions.
I would like to thank shareholders for their participation and for
their continued support and understanding in these exceptional
times".
|
Resolution
|
Total votes for(1)(2)
|
%
|
Total votes against(2)
|
%
|
Total votes cast
|
Votes withheld(3)
|
|
|
1
|
Receive and adopt the 2019 Annual Report
|
3,600,444,466
|
99.14
|
31,207,913
|
0.86
|
3,631,652,379
|
10,956,841
|
|
2
|
Approve the Annual report on remuneration
|
3,420,333,315
|
94.53
|
197,813,171
|
5.47
|
3,618,146,486
|
24,463,063
|
|
3
|
To approve the Remuneration policy
|
2,665,161,732
|
88.18
|
357,360,021
|
11.82
|
3,022,521,753
|
620,087,463
|
|
4
|
Election of Sir Jonathan Symonds
|
3,608,718,661
|
99.35
|
23,502,289
|
0.65
|
3,632,220,950
|
10,386,063
|
|
5
|
Election of Charles Bancroft
|
3,627,334,204
|
99.87
|
4,856,095
|
0.13
|
3,632,190,299
|
10,417,951
|
|
6
|
Re-election of Emma Walmsley
|
3,627,591,812
|
99.84
|
5,958,848
|
0.16
|
3,633,550,660
|
9,058,990
|
|
7
|
Re-election of Vindi Banga
|
3,610,251,798
|
99.39
|
22,061,718
|
0.61
|
3,632,313,516
|
10,290,761
|
|
8
|
Re-election of Dr Hal Barron
|
3,626,272,920
|
99.83
|
6,065,354
|
0.17
|
3,632,338,274
|
10,268,248
|
|
9
|
Re-election of Dr Vivienne Cox
|
3,610,563,927
|
99.39
|
21,999,262
|
0.61
|
3,632,563,189
|
10,044,077
|
|
10
|
Re-election of Lynn Elsenhans
|
3,625,704,253
|
99.82
|
6,692,345
|
0.18
|
3,632,396,598
|
10,211,321
|
|
11
|
Re-election of Dr Laurie Glimcher
|
3,627,888,440
|
99.87
|
4,570,015
|
0.13
|
3,632,458,455
|
10,149,465
|
|
12
|
Re-election of Dr Jesse Goodman
|
3,627,512,409
|
99.87
|
4,791,872
|
0.13
|
3,632,304,281
|
10,303,639
|
|
13
|
Re-election of Judy Lewent
|
3,555,987,248
|
97.90
|
76,330,162
|
2.10
|
3,632,317,410
|
10,290,509
|
|
14
|
Re-election of Iain Mackay
|
3,589,348,335
|
98.83
|
42,624,938
|
1.17
|
3,631,973,273
|
10,634,976
|
|
15
|
Re-election of Urs Rohner
|
3,566,736,006
|
98.27
|
62,967,560
|
1.73
|
3,629,703,566
|
10,694,898
|
|
16
|
Re-appointment of the auditor
|
3,629,594,188
|
99.89
|
4,085,942
|
0.11
|
3,633,680,130
|
8,926,613
|
|
17
|
Remuneration of auditor
|
3,628,076,303
|
99.86
|
4,927,253
|
0.14
|
3,633,003,556
|
9,605,108
|
|
18
|
Authority for the company to make donations to political
organisations and incur political expenditure
|
3,535,034,521
|
97.51
|
90,339,692
|
2.49
|
3,625,374,213
|
17,230,899
|
|
19
|
Authority to allot shares
|
3,486,912,340
|
96.08
|
142,428,115
|
3.92
|
3,629,340,455
|
13,259,348
|
|
20
|
Disapplication of pre-emption rights - general
power(4)
|
3,551,097,589
|
97.88
|
76,802,232
|
2.12
|
3,627,899,821
|
14,698,767
|
|
21
|
Disapplication of pre-emption rights - in connection with an
acquisition or specified capital investment(4)
|
3,547,842,037
|
97.88
|
76,869,347
|
2.12
|
3,624,711,384
|
17,887,616
|
|
22
|
Authority for the company to purchase its own
shares(4)
|
3,564,497,165
|
98.16
|
66,913,063
|
1.84
|
3,631,410,228
|
11,196,094
|
|
23
|
Exemption from statement of senior statutory auditor's
name
|
3,584,838,016
|
98.78
|
44,131,049
|
1.22
|
3,628,969,065
|
13,635,791
|
|
24
|
Authority for reduced notice of a general meeting other than an
AGM(4)
|
3,354,669,411
|
92.41
|
275,453,838
|
7.59
|
3,630,123,249
|
12,478,713
|
Notes:
|
(1)
|
The "for" votes include those giving the Chairman discretion. In
line with the notification issued to American Depositary Receipt
(ADR) holders last year, GSK did not instruct its ADR Depositary to
vote any unvoted ADRs in respect of the AGM
resolutions.
|
|
(2)
|
Votes "for" and "against" are expressed as a percentage of the
total votes cast.
|
|
(3)
|
A vote withheld is not a vote in law and is not counted in the
calculation of the proportion of votes "for" or "against" a
resolution.
|
|
(4)
|
Indicates Special Resolutions requiring a 75%
majority.
|
The following table provides further relevant
information:
|
|
GSK's
Twentieth
AGM
(2020)
|
GSK's
Nineteenth
AGM
(2019)
|
|
Issued share capital (excluding Treasury Shares)
|
5,017,091,542
|
4,987,806,108
|
|
Total votes cast and votes withheld lodged as a % of GSK's issued
share capital (excluding
Treasury Shares)
|
72.60%
|
71.49%
|
|
Total shareholder population
|
105,353
|
108,698
|
|
Total number of proxies lodged
|
6,268
|
6,635
|
|
% of shareholders who lodged proxies
|
5.95%
|
6.10%
|
The above poll results will shortly be available
on the Company's website at www.gsk.com.
In accordance with Listing Rule 9.6.2, a copy of the resolutions,
other than those concerning ordinary business, will be submitted to
the UK Listing Authority and will in due course be available for
inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism
V A Whyte
Company Secretary
6
May 2020
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: May
06, 2020
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|